“Abrocitinib in the Treatment of Moderate-to-Severe Atopic Dermatitis Refractory to Dupilumab Treatment: An Analysis of JADE-EXTEND, a Phase 3 Long-Term Extension Study”, J of Skin, vol. 7, no. 2, p. s153, Mar. 2023, doi: 10.25251/skin.7.supp.153.